XTX Topco Ltd Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

XTX Topco Ltd raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 57.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,631 shares of the specialty pharmaceutical company's stock after buying an additional 4,245 shares during the quarter. XTX Topco Ltd's holdings in Jazz Pharmaceuticals were worth $1,296,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of JAZZ. Itau Unibanco Holding S.A. acquired a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $29,000. EverSource Wealth Advisors LLC increased its stake in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after buying an additional 116 shares during the last quarter. Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth $33,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after buying an additional 704 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on JAZZ shares. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research note on Monday, August 19th. Piper Sandler reissued an "overweight" rating and set a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada boosted their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a research report on Wednesday, October 23rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $175.33.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded down $1.79 during midday trading on Monday, reaching $120.80. 464,804 shares of the company's stock traded hands, compared to its average volume of 669,682. The company has a market cap of $7.30 billion, a P/E ratio of 17.01, a PEG ratio of 1.04 and a beta of 0.57. The company has a fifty day simple moving average of $116.37 and a two-hundred day simple moving average of $111.75. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.